Efficacy of Nilotinib in CML-CP: Results from the ENEST Studies
CME INFORMATION

OVERVIEW OF ACTIVITY

The annual American Society of Hematology (ASH) meeting is unmatched in its importance with regard to advancements in hematologic cancer and related disorders. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results and new information lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across virtually all malignant and benign hematologic disorders. As online access to posters and plenary presentations is not currently available, a need exists for additional resources to distill the information presented at the ASH annual meeting for those clinicians unable to attend but desiring to remain up to date on the new data released there. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists, hematologists and hematology-oncology fellows in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES

- Apply emerging clinical trial data to the rational selection of treatment with targeted tyrosine kinase inhibitors for patients with refractory or relapsed chronic myeloid leukemia.
- Assess the risks of molecular relapse after the discontinuation of treatment with targeted tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
- Communicate the benefits and risks of therapy with multitargeted tyrosine kinase inhibitors for patients with newly diagnosed, relapsed or refractory chronic myeloid leukemia in chronic, accelerated or blast phase.
- Compare and contrast the benefits and adverse effects of continuous therapy with different targeted tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCASH2012/8/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and sponsors of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Srdan Verstovsek, MD, PhD
Associate Professor
Chief, Section of Myeloproliferative Neoplasms
Director, Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

No real or apparent conflicts of interest to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQile Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodex Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Allos Therapeutics, Celgene Corporation, Genentech BioOncology/ Biogen Idec, Incyte Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi and Seattle Genetics.

Expiration date: April 2013

Last review date: April 2012
To go directly to slides and commentary for this issue, click here.

The 2009 ASH meeting marked a high point in the amazing and continuing evolution of the management of chronic phase chronic myelogenous leukemia (CML-CP) with the sudden appearance of several convincing Phase III data sets demonstrating that the second-generation BCR-ABL TKIs nilotinib and dasatinib resulted in improvements in a number of major short-term endpoints and were equally or better tolerated compared to imatinib. These and other recent findings also put into sharp focus the fact that despite the impressive steps forward during the last decade there is room for improvement in CML-related outcomes, including survival. For this issue of our series we briefly review 8 new ASH data sets addressing the following important CML questions:

1. **What is the role of second-generation TKIs?**

The weight of evidence for the newer agents continues to mount, and at ASH another round of related data sets was reported.

**More follow-up on up-front nilotinib versus imatinib**

The landmark IRIS trial that established the role of imatinib demonstrated that most disease progression events occurred within 3 years, and as such similar follow-up with the newer TKIs is critical. At ASH, 3-year data from the ENESTnd trial of nilotinib versus imatinib revealed continued separation of the curves for major and deeper molecular response. Importantly, in the imatinib arm a 6% rate of progression to accelerated phase and blast crisis (AP/BC) was observed compared to only 0.7% with 300 mg BID of nilotinib.

**Switching TKIs at 1 year**

Many/most investigators currently prefer nilotinib or dasatinib as first-line therapy, but any imatinib holdouts will be forced to strongly consider the compelling preliminary results from the ENESTcmr Phase III trial assessing the benefit of switching therapy for individuals who do not achieve complete molecular response (CMR) after treatment with imatinib. In the study, 207 patients in complete cytogenetic response (CCyR) but with detectable BCR-ABL less than 2 years after starting imatinib were randomly assigned
to either continue therapy or switch to nilotinib 400 mg BID. At 12 months of follow-up, the rate of confirmed CMR was 5.8% with imatinib compared to 12.5% for nilotinib.

**Nilotinib 400 mg BID**

The ENESTnd extension trial reported at ASH evaluated the higher 400-mg BID dose of nilotinib in patients with suboptimal response or treatment failure on imatinib or nilotinib at 300 mg BID. The findings illustrate clear-cut efficacy in patients treated with prior imatinib — even after dose escalation — and also point to a benefit in those escalated to the higher nilotinib dose. Currently, 300 mg BID is still the recommended starting dose up front.

2. **Are there even newer TKIs with significant supportive trial data?**

**Ponatinib**

Ponatinib has been previously shown to have notable activity in tumors with otherwise problematic T315I mutations, and the clinical impact of this agent in resistant or intolerant disease was once again displayed in an impressive Phase II trial of 403 patients reported at ASH.

**Bosutinib**

Another data set presented at ASH came from the Phase III BELA trial comparing bosutinib to imatinib in patients with newly diagnosed CML-CP. The study did not meet its primary endpoint of CCyR at 12 months partly due to early treatment discontinuation in about a quarter of the patients related to bosutinib-associated adverse effects, particularly GI toxicity (diarrhea). However, other endpoints favored the new TKI bosutinib — including a lower rate of progression to AP/BC — and the future role of the agent is still up for debate.

3. **How early can suboptimal response be identified?**

The answer just might be 3 months, based on findings from an ASH presentation showing that patients on imatinib with >10% BCR-ABL levels or >35% Ph+ cells at the 3-month time point had a 5-year survival rate of only 87%. Ongoing trials are evaluating an early switch to another TKI in these patients.

4. **Can TKI treatment ever be stopped?**

Although disease control is everyone’s primary concern, lifelong TKI use introduces quality of life and financial constraints, and as such many have wondered if it is safe to stop therapy at some point. At ASH we saw results from the STIM study evaluating treatment discontinuation in 100 patients who received imatinib and experienced a CMR for at least 2 years. Interestingly, 61% of patients experienced molecular relapse upon
stopping therapy (almost all within 7 months). However, most went back into CMR with re-treatment. The ability to stay off the drug seemed to correlate with disease biology (Sokal score) and duration of therapy. Another ASH report of 25 patients who stopped either nilotinib or dasatinib seemed to reflect a similar conclusion, and indefinite treatment is still recommended outside a trial setting.


Neil Love, MD
Research To Practice
Miami, Florida
Efficacy of Nilotinib in CML-CP: Results from the ENEST Studies

Presentations discussed in this issue

Saglio G et al. Nilotinib versus imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 36-month (mo) follow-up. Proc ASH 2011; Abstract 452.

Hughes TP et al. Complete molecular response (CMR) rate with nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) without CMR after ≥ 2 years on imatinib: Preliminary results from the randomized ENESTcmr trial of nilotinib 400 mg twice daily (bid) vs imatinib. Proc ASH 2011; Abstract 606.

Hochhaus A et al. Results from the ENESTnd extension study: Efficacy and safety of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP), treated with nilotinib 400 mg twice daily (bid) after suboptimal response (SoR) or treatment failure (TF) to imatinib 400 mg once daily (qd) or nilotinib 300 mg bid. Proc ASH 2011; Abstract 114.

Slides from presentations at ASH 2011 and transcribed comments from a recent interview with Srdan Verstovsek, MD, PhD (1/25/12)
Nilotinib versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-Up

Saglio G et al. Proc ASH 2011;Abstract 452.

Background

- At a 2-year minimum follow up, the Phase III ENESTnd trial demonstrated that nilotinib is more effective than imatinib and is well tolerated in patients with newly diagnosed CML (Lancet Oncol 2011;12:841).

- However, historical data from the IRIS trial showed that most events of disease progression with imatinib occurred within the first 3 years of treatment (Leukemia 2009;23:1054).

- **Objective:**
  - Report on a 3-year minimum follow-up of ENESTnd to verify the benefits of nilotinib in patients with newly diagnosed CML.

Saglio G et al. Proc ASH 2011;Abstract 452.
**ENESTnd Trial Design**

**Eligibility (n = 846)**

- ≤6 months after diagnosis of chronic-phase Ph+ CML
- Diagnosis by conventional cytogenetic bone marrow analysis with ≥1 Ph+ metaphase cell
- Adequate organ function
- ECOG performance ≥2

Randomization was stratified by Sokal risk score
- Efficacy analysis based on the intent-to-treat population included all patients.
- Response assessments were performed during study treatment.
- Time to progression to accelerated-phase (AP)/blast crisis (BC) and overall survival (OS) were evaluated during follow-up every 3 months and after treatment discontinuation.

Saglio G et al. *Proc ASH 2011; Abstract 452.*

---

**Cumulative Incidence of Major Molecular Response (MMR)**

With permission from Saglio G et al. *Proc ASH 2011; Abstract 452.*
Cumulative Incidence of Deeper Molecular Response (MR^4*)

* Equivalent to BCR-ABL^15 transcript levels of ≤0.01%

With permission from Saglio G et al. Proc ASH 2011;Abstract 452.

Cumulative Incidence of Deeper Molecular Response (MR^4.5*)

* Equivalent to BCR-ABL^15 transcript levels of ≤0.0032%

Saglio G et al. Proc ASH 2011;Abstract 452.
Progression to AP/BC* on Core Treatment

*Progression to AP/BC or death following progression
*No new progressions occurred on core treatment since 2-year analysis.

With permission from Saglio G et al. Proc ASH 2011;Abstract 452.

Survival Outcomes

<table>
<thead>
<tr>
<th></th>
<th>Nilotinib 300 mg BID</th>
<th>Nilotinib 400 mg BID</th>
<th>Imatinib 400 mg QD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated 3-y OS</td>
<td>95.1%</td>
<td>97.0%</td>
<td>94.0%</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.8 (0.4-1.6)</td>
<td>0.5 (0.2-1.1)</td>
<td>—</td>
</tr>
<tr>
<td>p-value</td>
<td>0.4413</td>
<td>0.0639</td>
<td>—</td>
</tr>
</tbody>
</table>

- There were 38 deaths in total: nilotinib 300 mg (13), nilotinib 400 mg (8), imatinib 400 mg (17).
- Out of the total deaths, 23 occurred following progression to AP/BC: Nilotinib 300 mg (5), nilotinib 400 mg (4), imatinib 400 mg (14).

Saglio G et al. Proc ASH 2011;Abstract 452.
Author Conclusions

- Follow-up for 3 years confirmed the superiority of nilotinib over imatinib in the treatment of newly diagnosed CML-CP.
- Nilotinib demonstrated an acceptable tolerability profile in patients with newly diagnosed CML-CP (data not shown).
- Nilotinib continues to demonstrate:
  - Significantly higher and faster rates of MMR, MR4 and MR4.5.
  - Significantly higher responses across all Sokal risk groups (data not shown).
  - Significantly decreased risk of progression to AP/BC and death following progression.

Saglio G et al. Proc ASH 2011;Abstract 452.

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results from the Randomized ENEStcmr Trial of Nilotinib 400 Mg Twice Daily (BID) vs Imatinib

Hughes TP et al. Proc ASH 2011;Abstract 606.
Background

- Previous studies showed that 40% of patients with CML-CP who achieved durable CMR after treatment with imatinib were able to cease therapy without recurrence (Lancet Oncol 2010;11:1029).
- A large portion of patients (55%) with CML do not achieve CMR on imatinib, even with long-term therapy (>6 y) (Clin Cancer Res 2007;13:7080).
- In the ENEStnd trial, the number of patients who achieved MMR, MR^4 and MR^4.5 was significantly higher with nilotinib therapy than with imatinib (Lancet Oncol 2011;12:841).

**Objective:**
- Determine whether patients with CML-CP on long-term imatinib would be more likely to achieve undetectable BCR-ABL levels if therapy were switched to nilotinib.

Hughes TP et al. Proc ASH 2011;Abstract 606.

Study Design

**Eligibility (n = 207)**

- Prior imatinib therapy (400 or 600 mg/d) for ≥2 y for Ph+ CML-CP
- Documented CCyR or 2 positive BCR-ABL transcript levels by RQ-PCR in ≤9 mo
- Adequate organ function
- QTcF <450 ms

**Primary endpoint**
- Confirmed CMR (undetectable BCR-ABL [with ≥4.5-log assay sensitivity]) by 12 months

**Secondary endpoints**
- Kinetics of molecular response (RQ-PCR for primary and secondary endpoints were performed every 3 months)
- Safety profile

Hughes TP et al. Proc ASH 2011;Abstract 606.
Primary Endpoint in the Intention-to-Treat Population

- The intention-to-treat population included all patients randomized to the study.
- At 12 months, 14.9% of patients on nilotinib vs 6.1% on imatinib achieved confirmed CMR ($p = 0.04$).

With permission from Hughes TP et al. *Proc ASH* 2011;Abstract 606.

Molecular Response* in Patients without Indicated Response at Baseline

* Follow-up period of 12 months
† With ≥4.5-log assay sensitivity

With permission from Hughes TP et al. *Proc ASH* 2011;Abstract 606.
Drug-Related Adverse Events (AEs)

<table>
<thead>
<tr>
<th>Event</th>
<th>Nilotinib (n = 104)</th>
<th>Imatinib (n = 103)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any AE</td>
<td>88%</td>
<td>53%</td>
</tr>
<tr>
<td>Grade 3/4 AEs</td>
<td>29%</td>
<td>2%</td>
</tr>
<tr>
<td>AEs leading to discontinuation</td>
<td>9%</td>
<td>0%</td>
</tr>
<tr>
<td>Serious AEs</td>
<td>4%</td>
<td>0%</td>
</tr>
</tbody>
</table>

- Patients experienced AEs early on nilotinib after switch from long-term imatinib therapy.
- However, these AEs were expected and consistent with the safety profile of nilotinib observed in other studies.


Author Conclusions

- For patients with ongoing BCR-ABL-positivity on imatinib therapy, switching to nilotinib leads to faster and deeper molecular responses.
- Deeper molecular responses on nilotinib therapy may increase the eligibility of patients for future TKI discontinuation studies.
- The ultimate success of this strategy will be assessed in the prospective ENEStop discontinuation study.

Investigator Commentary:
Nilotinib versus Imatinib in Patients with Newly Diagnosed Ph+ CML-Cp: 36-Month ENESTnd Follow-Up

CMR Rate with Nilotinib in Patients with CML-CP without CMR After ≥2 y on Imatinib: Preliminary Results from ENESTcmr Trial

Nilotinib was approved as front-line therapy for patients with chronic myeloid leukemia in chronic phase. These reports confirmed the long-term efficacy and safety of nilotinib versus imatinib. In particular, these studies confirmed that nilotinib therapy results in lower rates of disease progression and treatment discontinuation in comparison to imatinib. These 2 reports demonstrate the utility and choice of nilotinib as first-line therapy for patients with CML-CP.

*Interview with Srdan Verstovsek, MD, PhD, January 25, 2012*

Results from the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-Cp), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID

Hochhaus A et al.  
*Proc ASH 2011;Abstract 114.*
# Study Design

Patients initially assigned on ENEStnd trial

- **Nilotinib (n = 18)**
  - 300 mg BID

- **Imatinib (n = 31)**
  - 400 mg QD

**SoR/TF**

**ENEST extension study to determine efficacy and safety**

- **Nilotinib (n = 49)**
  - 400 mg BID

**SOR/TF**, suboptimal response/treatment failure

**TF**: no CyR at 6 months; <partial CyR (PCyR) at 12 months; <CCyR at 18 months; loss of confirmed complete hematologic response, PCyR, CCyR, progression to AP/BC or clonal evolution at any time

**SoR**: <PCyR at 6 months; <CCyR at 12 months; <MMR at 18 months

- Entrance into the extension study was not allowed for intolerance.


---

# Reason for Patient Entry Into ENESt Extension Study (Abstract Only)

<table>
<thead>
<tr>
<th>Reason</th>
<th>Initially assigned to ENEStnd nilotinib (n = 18)</th>
<th>Initially assigned to ENEStnd imatinib* (n = 31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TF</td>
<td>17%</td>
<td>68%</td>
</tr>
<tr>
<td>SoR</td>
<td>78%</td>
<td>26%</td>
</tr>
<tr>
<td>Other†</td>
<td>6%</td>
<td>6%</td>
</tr>
</tbody>
</table>

* Patients (n = 20) escalated to 400 mg/d of imatinib before extension study entry.

† Entry into extension study per investigator assessment without satisfying SOR/TF criteria

# Extension Treatment Outcomes (Abstract Only)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Nilotinib (n, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response during extension</td>
<td></td>
</tr>
<tr>
<td>Response prior to entry: (&lt;CCyR (n = 6)</td>
<td>1 (17%)</td>
</tr>
<tr>
<td>Response prior to entry: (&lt;MMR (n = 17)</td>
<td>5 (29%)</td>
</tr>
<tr>
<td>Progression to AP/BC</td>
<td></td>
</tr>
<tr>
<td>≤1 month after discontinuation</td>
<td>1 (6%)</td>
</tr>
<tr>
<td></td>
<td>1 (6%)</td>
</tr>
<tr>
<td><strong>Outcome achieved during ENEST extension</strong></td>
<td></td>
</tr>
<tr>
<td>Response during extension</td>
<td></td>
</tr>
<tr>
<td>Response prior to entry: (&lt;CCyR (n = 26)</td>
<td>12 (46%)</td>
</tr>
<tr>
<td>Response prior entry: (&lt;MMR (n = 30)</td>
<td>7 (23%)</td>
</tr>
<tr>
<td>Progression to AP/BC</td>
<td></td>
</tr>
<tr>
<td>During extension study</td>
<td></td>
</tr>
<tr>
<td>≤1 month after discontinuation</td>
<td>13%</td>
</tr>
<tr>
<td>&gt;12 months after discontinuation</td>
<td>7%</td>
</tr>
<tr>
<td></td>
<td>3%</td>
</tr>
<tr>
<td></td>
<td>3%</td>
</tr>
</tbody>
</table>

Hochhaus A et al. *Proc ASH 2011; Abstract 114.*

# Adverse Events (AEs) (Abstract Only)

<table>
<thead>
<tr>
<th>Event</th>
<th>Nilotinib (n = 18)</th>
<th>Imatinib (n = 31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3/4 AEs</td>
<td>28%</td>
<td>52%</td>
</tr>
<tr>
<td>Drug-related AEs leading to discontinuation</td>
<td>0%</td>
<td>10%</td>
</tr>
<tr>
<td>Deaths*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>During extension treatment or ≤28 d of discontinuation</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

*Deaths (n = 4) occurred >28 days after treatment discontinuation: 3 were CML related (1 and 2 for nilotinib and imatinib, respectively) and occurred 8-10 months after discontinuation

Hochhaus A et al. *Proc ASH 2011; Abstract 114.*
Author Conclusions

- These data confirm the efficacy of nilotinib at 400 mg BID for patients with CML-CP who had SOR or TF, even after dose escalation of imatinib.
- Although dose escalation of imatinib may overcome OCT-1 transporter activity in patients with correspondingly low imatinib plasma levels, nilotinib is not a substrate for OCT-1.
- Although further evaluation is required, the modest (~16%) increase in systemic exposure to nilotinib from 300 to 400 mg BID may benefit some patients with SoR/TF.
- Dose escalation of nilotinib from 300 to 400 mg BID appears safe with no additional safety signals.
- The extension study is ongoing and additional follow-up results will provide further information.


Investigator Commentary: Results from the ENESTnd Extension Study — Efficacy and Safety of 400 mg BID of Nilotinib in Patients with CML-CP after SOR/TF

Nilotinib is becoming a strong player for front-line therapy instead of imatinib in patients with CML-CP. It is one of the major agents that improves outcomes as second-line treatment when there is no optimal response to imatinib. Based on these data, nilotinib therapy quickly produced better responses than imatinib, particularly molecular responses, and also has an excellent toxicity profile.

Therefore, nilotinib is a viable first choice as front-line therapy because there is good evidence from several studies that a rapid and deep response is crucial for long-term outcomes in patients with CML-CP.

Interview with Srdan Verstovsek, MD, PhD, January 25, 2012